Use of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) with or without ribavirin is very effective in the treatment of chronic hepatitis C with advanced hepatic fibrosis or compensated cirrhosis, according to a recent study, adding that Child-Pugh A6 must be an exclusion criterion for first-line treatment in these patients.
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
The low uptake of the human papillomavirus (HPV) vaccine in the US and strategies to improve HPV vaccine coverage were highlighted in two studies presented at the Pediatric Academic Societies annual meeting (PAS 2019).
Tofacitinib yields clinical and radiographic improvements in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, and such improvements are sustained for up to 24 months without new safety signals, according to the results of the phase III ORAL* Scan trial.
Recent continuous use of methotrexate (MTX) is associated with a 20-percent decrease in cardiovascular events (CVE) in patients with early-onset rheumatoid arthritis (RA), a recent study has shown. In addition, greater MTX use in the first year of cohort entry appears to lower the risk of CVE.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).
About half of the patients who initiate statin therapy for primary prevention of cardiovascular disease (CVD) fail to achieve optimal reduction in their low-density lipoprotein cholesterol (LDL-C) levels within 2 years, as reported in a recent study. At the heart of this is that a suboptimal response further raises the risk of developing future CVD.
Eribulin is as effective as dacarbazine in patients with leiomyosarcoma (LMS), with both agents showing manageable safety profiles, results of a subgroup analysis from a phase III, open-label, randomized study have shown.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.